These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19252248)

  • 21. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
    Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
    Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New bone density conservation agents for osteoporosis under research and development: Anti-RANKL antibody].
    Wada S; Fukawa T; Kamiya S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():459-62. PubMed ID: 18161149
    [No Abstract]   [Full Text] [Related]  

  • 23. [RANKL/RANK signaling in rheumatoid arthritis].
    Omata Y; Tanaka S
    Clin Calcium; 2011 Aug; 21(8):1175-80. PubMed ID: 21814022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
    Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
    J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RANKL: A therapeutic target for bone destruction in rheumatoid arthritis.
    Tanaka S; Tanaka Y; Ishiguro N; Yamanaka H; Takeuchi T
    Mod Rheumatol; 2018 Jan; 28(1):9-16. PubMed ID: 28880683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The impact of controlling bone remodeling in rheumatoid arthritis.].
    Ebina K
    Clin Calcium; 2017; 27(12):1739-1744. PubMed ID: 29179168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Myeloma bone disease and RANKL signaling].
    Abe M
    Clin Calcium; 2011 Aug; 21(8):1167-74. PubMed ID: 21814021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [RANKL inhibition as therapy for joint damage].
    Akama H
    Nihon Rinsho Meneki Gakkai Kaishi; 2007 Oct; 30(5):404-7. PubMed ID: 17984581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis.
    Hamdy NA
    Curr Opin Investig Drugs; 2007 Apr; 8(4):299-303. PubMed ID: 17458179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Present and future of the treatment of osteoporosis with monoclonal antibodies].
    Fiter Aresté J
    Reumatol Clin; 2011 Sep; 7 Suppl 2():S8-12. PubMed ID: 21924213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system.
    Tanaka Y; Ohira T
    Curr Opin Pharmacol; 2018 Jun; 40():110-119. PubMed ID: 29702364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
    Tanaka S
    Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis.
    Sharp JT; Tsuji W; Ory P; Harper-Barek C; Wang H; Newmark R
    Arthritis Care Res (Hoboken); 2010 Apr; 62(4):537-44. PubMed ID: 20391509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging anti-osteoclast therapy for rheumatoid arthritis.
    Tanaka S
    J Orthop Sci; 2018 Sep; 23(5):717-721. PubMed ID: 30075997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
    Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
    Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis.
    Chao CC; Chen SJ; Adamopoulos IE; Davis N; Hong K; Vu A; Kwan S; Fayadat-Dilman L; Asio A; Bowman EP
    Autoimmunity; 2011 May; 44(3):243-52. PubMed ID: 20925596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis.
    Ho TY; Santora K; Chen JC; Frankshun AL; Bagnell CA
    Bone; 2011 Jun; 48(6):1346-53. PubMed ID: 21419242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RANKL as a therapeutic target of rheumatoid arthritis.
    Tanaka S; Tanaka Y
    J Bone Miner Metab; 2021 Jan; 39(1):106-112. PubMed ID: 33070253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.